CureVac’s CEO, Ingmar Hoerr, Appointed by European Commission to High Level Group

The High Level Group of Innovators brings together leading personalities from across Europe with a wide range of expertise in business innovation, including entrepreneurs, CEOs, investors and other major players in the innovation ecosystem.

Ingmar Hoerr, Ph.D., co-founder and CEO of CureVac, stated: “It is a tremendous honor to be selected by the European Commission as member of the High Level Group focused on advancing innovation throughout the European Union. As one of the pioneering companies in mRNA therapeutics, CureVac is at the forefront of medical innovation, and I am delighted that our experience and leadership will benefit the next generation of European entrepreneurs who are seeking to improve the world through science.”

Read the press release of the European Commission here.

Download press notice as PDF file.

Your contact

Verena Lauterbach
Senior Manager Communications
T: +49 7071 9883 1756
contact via e-mail